MedTrace Logo

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

NCT00429533 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2007-02-05

No results posted yet for this study

Summary

The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.

Conditions

  • Pemphigus Vulgaris

Interventions

DRUG

Dapsone

Sponsors & Collaborators

  • Jacobus Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Victoria P. Werth, MD · University of Pennsylvania

  • Victoria P. Werth, MD · University of Pennsylvania

  • Diana Chen, MD · Northwestern University

  • Warren R Heymann, MD · Cooper Hospital/University Medical Center

  • Neil Korman, MD · Case Western Reserve University School of Medicine

  • Amit Pandya, MD · University of Texas

  • M J Rico, MD · The New York VA Medical Center - New York University

  • Michael D Tharp, MD · Rush University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-11-30
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429533 on ClinicalTrials.gov